5/10/2022 6:44:24 AM
Reata Pharma Q1 GAAP Net Loss $73.8 Mln Or $2.03/Shr Vs Loss Of $67.5 Mln Or $1.86/Shr Last Year
2/28/2022 6:48:42 AM
Reata Pharma FY GAAP Net Loss $297.4 Mln Or $8.19/Shr Vs Loss Of $247.8 Mln Or $7.35/Shr Last Year
1/31/2022 6:49:00 AM
Reata Initiates Rolling Submission Of NDA With FDA For Omaveloxolone For Friedreich's Ataxia Treatment
12/8/2021 7:40:35 AM
Reata Pharma: FDA Advisory Committee To Discuss Bardoxolone For Chronic Kidney Disease Caused By Alport Syndrome
3/1/2021 6:41:50 AM
Reata Pharma FY GAAP Loss Per Share $7.35; Non-GAAP Loss Per Share $4.70